Figure 2From: High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility studyDramatic partial response in patient with liver, lymph nodes and subcutaneous metastases treated in Cohort B (schedule d1-21).Back to article page